Table 4 Administration of abobotulinumtoxinA at baseline by muscle
Muscle | AbobotulinumtoxinA treated subjects (N = 1202) |
|---|---|
Splenius capitis | N = 1087 |
Dose (U); mean ± SD | 226 ± 134 |
Dose (U); median [range] | 200 [10–1100] |
Volume (mL); median [range] | 0.75 [0.1–4.4] |
Number of injection points; median [range] | 2 [1–12] |
Use of injection guidance (%)* | 40.1 |
Sternocleidomastoid | N = 967 |
Dose (U); mean ± SD | 147 ± 81 |
Dose (U); median [range] | 130 [15–600] |
Volume (mL); median [range] | 0.50 [0.1–2.8] |
Number of injection points; median [range] | 2 [1–10] |
Use of injection guidance (%)* | 38.0 |
Trapezius | N = 739 |
Dose (U); mean ± SD | 163 ± 111 |
Dose (U); median [range] | 140 [10–1000] |
Volume (mL); median [range] | 0.50 [0.1–5.3] |
Number of injection points; median [range] | 2 [1–12] |
Use of injection guidance (%)* | 34.9 |
Levator scapulae | N = 569 |
Dose (U); mean ± SD | 125 ± 82 |
Dose (U); median [range] | 100 [13–550] |
Volume (mL); median [range] | 0.40 [0.1–2.8] |
Number of injection points; median [range] | 1 [1–10] |
Use of injection guidance (%)* | 48.9 |
Semispinalis capitis | N = 334 |
Dose (U); mean ± SD | 138 ± 84 |
Dose (U); median [range] | 100 [10–500] |
Volume (mL); median [range] | 0.50 [0.1–2.2] |
Number of injection points; median [range] | 2 [1–8] |
Use of injection guidance (%)* | 49.4 |
Scalene group** | N = 164 |
Dose (U); mean ± SD | 100 ± 68 |
Dose (U); median [range] | 85 [13–450] |
Volume (mL); median [range] | 0.30 [0.1–1.5] |
Number of injection points; median [range] | 2 [1–8] |
Use of injection guidance (%)* | 50.0 |
Longissimus group*** | N = 86 |
Dose (U); mean ± SD | 128 ± 66 |
Dose (U); median [range] | 100 [20–300] |
Volume (mL); median [range] | 0.40 [0.0–1.2] |
Number of injection points; median [range] | 2 [1–8] |
Use of injection guidance (%)* | 64.0 |
Splenius cervicis | N = 60 |
Dose (U); mean ± SD | 122 ± 79 |
Dose (U); median [range] | 100 [20–500] |
Volume (mL); median [range] | 0.50 [0.1–1.6] |
Number of injection points; median [range] | 1 [1–11] |
Use of injection guidance (%)* | 65.0 |
Obliquus capitis inferior | N = 42 |
Dose (U); mean ± SD | 75 ± 44 |
Dose (U); median [range] | 60 [20–250] |
Volume (mL); median [range] | 0.30 [0.1–1.3] |
Number of injection points; median [range] | 1 [1–2] |
Use of injection guidance (%)* | 93.0 |
Platysma | N = 24 |
Dose (U); mean ± SD | 72 ± 33 |
Dose (U); median [range] | 60 [30–170] |
Volume (mL); median [range] | 0.25 [0.1–0.9] |
Number of injection points; median [range] | 4 [1–12] |
Use of injection guidance (%)* | 12.5 |